Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 21

Results For "clinical-trial"

805 News Found

Moderna announces positive Phase 3 efficacy data for next generation COVID-19 vaccine
Diagnostic Center | June 14, 2024

Moderna announces positive Phase 3 efficacy data for next generation COVID-19 vaccine

Higher efficacy was observed in mRNA-1283 compared to Spikevax in adults 18 years of age and older


Farxiga approved in the US for the treatment of paediatric type-2 diabetes
Drug Approval | June 14, 2024

Farxiga approved in the US for the treatment of paediatric type-2 diabetes

Approval based on results from T2NOW, one of the largest paediatric type-2 diabetes Phase III trials to date


Moderna & Merck announce 3-year data for mRNA-4157 in combination with Keytruda
Diagnostic Center | June 05, 2024

Moderna & Merck announce 3-year data for mRNA-4157 in combination with Keytruda

The companies have initiated Phase 3 studies in patients with high-risk melanoma and non-small cell lung cancer


Merck's oncology pipeline of DDRi and ADC poised to advance cancer treatment
Diagnostic Center | June 04, 2024

Merck's oncology pipeline of DDRi and ADC poised to advance cancer treatment

Merck shared updates on the company’s oncology pipeline and focused R&D approach


AbbVie receives positive CHMP opinion for Risankizumab for treatment ulcerative colitis
News | June 01, 2024

AbbVie receives positive CHMP opinion for Risankizumab for treatment ulcerative colitis

Ulcerative Colitis (UC) is a chronic, idiopathic, immune-mediated inflammatory bowel disease (IBD) affecting the large intestine


BlueRock Therapeutics receives FDA RMAT designation for Parkinson’s disease cell therapy candidate bemdaneprocel
Drug Approval | May 31, 2024

BlueRock Therapeutics receives FDA RMAT designation for Parkinson’s disease cell therapy candidate bemdaneprocel

Bemdaneprocel is the most clinically advanced investigational cell therapy in the U.S. for treating patients living with Parkinson’s disease


IGC Pharma announces patient enrollment at Neurostudies in Phase 2 trial investigating IGC-AD1
News | May 29, 2024

IGC Pharma announces patient enrollment at Neurostudies in Phase 2 trial investigating IGC-AD1

Advancing IGC-AD1 Toward Commercialization as a Treatment for Agitation in Alzheimer's


Bluecrux supports Sanofi in harnessing AI to transform supply chains
Supply Chain | May 28, 2024

Bluecrux supports Sanofi in harnessing AI to transform supply chains

Bluecrux's digital supply chain twin technology, Axon, plays a critical role in Sanofi's digital supply chain transformation.


Novartis atrasentan Phase III data show clinically meaningful proteinuria reduction
Diagnostic Center | May 27, 2024

Novartis atrasentan Phase III data show clinically meaningful proteinuria reduction

Through its rare kidney disease portfolio, Novartis is committed to exploring a range of treatment options with different modes of action to slow IgAN progression


Heuron gets FDA green light for stroke triage and notification solution
News | May 25, 2024

Heuron gets FDA green light for stroke triage and notification solution

This marks the first FDA approval of an AI-based brain disorder analysis solution from Korea